Betting Generic: Part D, Patents and Proteins Drive Investment Surge
This article was originally published in RPM Report
Executive Summary
Generic drug companies have been spurned by Wall Street in the past in favor of their brand manufacturing counterparts. With high generic use rates in Medicare Part D and a perceived inevitability of follow-on biologics, investment in pharmaceutical copycats is on the upswing.